Introduction: The aim of this multicenter study was to assess the efficacy and safety of injecting a fluocinolone acetonide implant (FACi) one month after the last dexamethasone implant (DEXi) intravitreal injection (IVI) in chronic diabetic macular edema (DME) patients, as a Methods: This retrospective study evaluated a standardised care protocol implemented across five centres. Inclusion criteria were: pseudophakic, chronic DME treated with DEXi every 30 mmHg” event was 2.7% 0.0; 12.2 at M12 and 18.8% 7.2; 34.4 at M36. One patient underwent incisional surgery (Xen Stent implantation). Conclusion: Injecting FACi one month after the last DEXi in patients requiring DEXi IVI every <6 months allowed maintaining the BCVA while spacing out or even discontinuing IVI with limited IOP concerns.
Delperier et al. (Fri,) studied this question.